Rizatriptan-Benzoate shortage — AU supply status & alternatives | Mederti
Rizatriptan-Benzoate
—
Limited supply · Australia
RIXALT rizatriptan
In declared shortage · 🇦🇺 Australia
Limited supply
Reading today’s signals…
✓ Can I substitute?
Per normal rules
Confirm with prescriber
⇄ Best alternative
None listed
refer to prescriber
◷ Expected back
July 2026
Sponsor est. via TGA
Product attributes reference data we hold
Active ingredient (INN)
Rizatriptan-Benzoate
Brand names
RIXALT rizatriptan
Therapeutic category
Auto-created by TGA backfill
Controlled substance
No
Patient information leaflet (PIL)
Not on file
Summary of product characteristics (SPC)
Not on file
Trade price 🇦🇺 Australia · awaiting price ingest
🇦🇺 AU
Ex-manufacturer
—
Dispensed (DPMQ)
—
Pack
—
$
Not yet captured for Australia
Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.
Substitution pathways 🇦🇺 Australia · TGA
—
No substitution instrument in force
Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.
How long have past shortages lasted? from 1 resolved event
◷
~1 month
Historical pattern from resolved shortage records — not a prediction of this event.
Generated 1 July 2026 · Australia market · 1 regulatory source
For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.